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Key Points
• Phospho-ERK1/2 lev-
els in peripheral blood
CD41 T cells at day 30
after allo-HSCT may be
a biomarker of human
acute GVHD.
•Our results provide
a rationale for the effi-
cacy of MEK inhibitors
against human GVHD.
To diagnose graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell
transplantation (allo-HSCT) is sometimes difficult. We showed previously that MEK
inhibitors selectively suppress murine GVHD while retaining antiviral and antitumor
immunity. Here, we asked whether the RAS/MEK/ERK pathway is activated in human
allo-HSCT recipients with GVHD, and whether the phosphorylated ERK1/2 can be
a biomarker of GVHD. Peripheral blood was sequentially collected from 20 allo-HSCT
recipients: 1 bone marrow transplant, 7 peripheral blood stem cell transplants (PBSCT),
and 12 cord blood transplants. Ten of the 20 allo-HSCT recipients developed GVHD,
and phosphorylation of ERK1/2 in T and B cells was analyzed by flow cytometry. Occurrence
of acute GVHD was associated with phosphorylation of ERK1/2 in CD41 T cells at day 30
(P , .001), which was suppressed by ex vivo exposure to a MEK inhibitor trametinib at
clinically achievable concentrations. In particular, ERK1/2 was phosphorylated
preferentially in naive/central memory CD41 T cells. Notably, phosphorylation of ERK1/2
fell as GVHD improved. These results suggest that phosphorylation status of ERK1/2 in
peripheral blood CD41 T cells may be a future biomarker for diagnosing human GVHD,
and the potential efficacy of MEK inhibitors against human GVHD.
Introduction
After allogeneic hematopoietic stem cell transplantation (allo-HSCT), donor-derived T cells trigger
host tissue injury; that is, graft-versus-host disease (GVHD).1-3 Although currently available immunosup-
pressants reduce GVHD, they also suppress antiviral/antitumor T cells, which can result in fatal
opportunistic infections4 and relapse of hematologic malignancy.5
Recently, we showed that MEK inhibitors selectively suppress naive and central memory T cells in vitro
while preserving the activity of effector memory T cells.6 We then confirmed that a MEK inhibitor
trametinib selectively suppresses GVHD while retaining antitumor immunity in vivo,7 and that it also
attenuates delayed rejection sparing thymic function after lung transplantation.8 Although these findings
should be verified in clinical trials, the importance of the MEK/ERK pathway in human GVHD is still
unclear.
The diagnosis of GVHD mainly depends on pathological evaluation. However, correct diagnosis is often
difficult because of the unavailability of fair and sufficient specimens. As currently available laboratory
tests have limitations, more specific biomarkers of GVHD are needed.
Here, we asked whether the RAS/MEK/ERK pathway is activated in T cells of patients with GVHD.
In addition, we asked whether phosphorylation status of ERK1/2 in peripheral blood T cells can be
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a predictive and diagnostic biomarker for GVHD by examin-
ing the association between phosphorylated ERK1/2 levels in
T cells and the occurrence of GVHD. Finally, we exposed T cells
to trametinib ex vivo to estimate the dose required to suppress
GVHD.
Study design
Twenty allo-HSCT recipients at Saga University Hospital and Kobe
City Medical Center General Hospital from May 2016 through
May 2017 were enrolled. Their clinical characteristics are summa-
rized in Table 1. All patients achieved complete chimerism with
donor type. Peripheral blood mononuclear cells (PBMCs) were
collected sequentially on days 30, 60, and 90 post–allo-HSCT.
The used antibodies and reagents are described in supplemental
Materials. Trametinib and tacrolimus were purchased from Selleck
Chemicals (Houston, TX), and detailed protocols of in vitro and
ex vivo experiments are described in supplemental Materials.
The study was approved by the Institutional Review Boards of
Saga University Hospital and Kobe City Medical Center General
Hospital.
Results and discussion
The clinical characteristics of the patients are summarized in
Table 1 and supplemental Materials. Ten patients (50%) de-
veloped acute GVHD at days 13 to 34 (median, day 24); 5 (50%)
of these developed grade III to IV GVHD. One patient with acute
GVHD later developed chronic GVHD. Patients with acute GVHD
showed slightly delayed reconstitution of lymphocytes at days
30 and 90 (supplemental Figure 1A-B). Five patients with acute
GVHD had viral infectious episodes: 4 cases after the develop-
ment of GVHD and 1 case simultaneously with GVHD, which may
be associated with delayed immune reconstitution (supplemental
Table 1).
To evaluate the potential role of the RAS/MEK/ERK signal-
ing pathway in GVHD, we analyzed phosphorylation status
of ERK1/2 in peripheral blood T and B cells stimulated with or
without phorbol 12-myristate 13-acetat (PMA) and ionomycin.
Notably, phospho-ERK1/2 levels at day 30 were higher,
particularly in CD41 T cells from patients with acute GVHD
than in patients without GVHD (P , .001; Figure 1A-B).
In contrast, phospho-ERK1/2 levels in CD81 T and CD191
B cells from patients with GVHD were equivalent to those
in patients without GVHD (Figure 1C-D). Phospho-ERK1/2
levels at day 30 were higher in CD41-naive (CD271CD45RA1)
and central memory (CD271CD45RA2) T cells in patients with
acute GVHD than in patients without GVHD (P 5 .003 and
P 5 .022; Figure 1E-F). There was no difference in phospho-
ERK1/2 levels in effector memory T cells (CD272CD45RA2)
between patients with GVHD and patients without GVHD
(Figure 1G). Furthermore, we found that phospho-ERK1/2
levels were associated with clinical course. One patient
who developed grade III acute GVHD at day 30 received
prednisolone pulse therapy; GVHD improved by day 60 and
coincided with decreased expression of phospho-ERK1/2
(Figure 1H).
To investigate whether trametinib suppresses activation of
RAS/MEK/ERK signaling in CD41 and CD81 T cells of the
patients, PBMCs of the patients with GVHD at day 30 were
stimulated ex vivo with PMA/ionomycin and trametinib or tacrolimus
at differential concentrations (Figure 2A-B). Trametinib strongly
suppressed phosphorylation of ERK1/2 in CD41 T, CD81 T,
and CD191 B cells in a dose-dependent manner, whereas
tacrolimus did not. Based on pharmacokinetics of trametinib in
patients with melanoma,9 our results indicate that its clinically
achievable concentrations suppress activation of the MEK/ERK
pathway in T and B cells of patients with GVHD.
Table 1. Patient characteristics
Characteristics GVHD-positive GVHD-negative P
Total number 10 10
Male, n (%) 8 (80) 6 (60) .3553
Age, median (range), y 55 (20-62) 50 (21-66) .5620
Onset of acute GVHD, median (range), d 24 (13-34)




Onset of chronic GVHD, n (%) 1 (10) 0 (0)
WBC count, mean, 3109/L
Day 30 3.217 3.134 .9143
Day 60 5.909 5.927 .9917
Day 90 6.355 5.242 .5381
Lymphocyte count, mean, 3109/L
Day 30 0.330 0.602 .0858
Day 60 0.881 1.159 .6095
Day 90 0.830 1.426 .0911
Disease, n (%)
AML/MDS 6 (60) 5 (50)
ALL 0 (0) 2 (20)
ML/ATLL 2 (20) 1 (10)
Other 2 (20) 2 (20)
Donor source
BMT 0 (0) 1 (10)
PBSCT 2 (20) 4 (40)
CBT 8 (80) 4 (40)
Haplo 0 (0) 1 (10)
Conditioning, n (%)
MAC 3 (30) 3 (30)
RIST 7 (70) 7 (70)
Immunosuppressant, n (%)
FK base 10 (100) 9 (90)
CyA base 0 (0) 1 (10)
1ATG 0 (0) 4 (40)
1PT-CY 0 (0) 1 (10)
Relapse after HSCT 1 (10) 3 (30)
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte
globulin; ATLL, adult T-cell leukemia/lymphoma; BMT, bone marrow transplantation; CBT,
cord blood transplantation; CyA, cyclosporine; FK, tacrolimus; Haplo, haploidentical
transplantation; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; ML,
malignant lymphoma; PBSCT, peripheral blood stem cell transplantation; RIST, reduced-
intensity hematopoietic stem cell transplantation; PT-CY, post-transplant
cyclophosphamide.
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Several studies indicate that alloreactivity of premature T cells
without any antigenic memory might trigger GVHD after allo-
HSCT.10-12 In addition, central memory T cells may play a role in
GVHD.13 We previously showed that MEK inhibitors suppress
GVHD without abrogating antiviral/antitumor immunity by selec-
tively suppressing naı¨ve/central memory T cells.6,7 Here, our results
point specifically to the clinical significance of the MEK/ERK
pathway within these cell subsets. Although several biomarkers
have been raised as for acute GVHD,14-16 none has been validated
as a predictor of either the risk of developing acute GVHD or
responsiveness to treatment. We suggest that the risk for GVHD
and the therapeutic effects of drugs can be evaluated by analyzing
the activation status of the RAS/MEK/ERK signaling pathway in
CD41 T cells; that is, this may be a marker of the development and
persistence of acute GVHD.
We examined the association between the RAS/MEK/ERK
pathway activation in T and B lymphocytes and occurrence of
acute GVHD after allo-HSCT. Notably, phosphorylation of ERK1/2
in CD41 T cells was positively associated with acute GVHD.
In particular, phospho-ERK1/2 levels in naive and central memory
CD41 T cells were associated strongly with acute GVHD. Although
further validation is still needed, these results suggest that
the RAS/MEK/ERK signaling plays a significant role in human
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Figure 1. Phospho-ERK1/2 levels in
CD41-naive and central memory T cells
at day 30 were positively correlated with acute
GVHD. PBMCs from allo-HSCT recipients were
stimulated with or without PMA and ionomycin, and
phosphorylation of ERK1/2 was analyzed by flow
cytometry (gating on CD41, CD81, and CD191 cells).
Closed circles, patients with GVHD; open circles,
patients without GVHD. (A) Representative histo-
grams showing CD41 T cells from patients with
and without GVHD are presented. Aggregated
percentages of cells from respective cell subsets
expressing phospho-ERK1/2 are shown. Samples
stimulated with PMA and ionomycin are shown in
gray, and unstimulated samples are shown in red.
Percentages of CD41 T cells (B), CD81 T cells
(C), CD191 B cells (D), CD41-naive T cells (E),
CD41 central memory T cells (F), and CD41
effector memory T cells (G) (n 5 10 per group;
data are expressed as means 6 SEMs). (H) Clinical
course of GVHD, immunosuppressants used and
phospho-ERK1/2 levels in CD41 T cells at days 30
and 60. *P , .05; **P , .01 (unpaired 2-tailed
Student t test). n.s., not significant.
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Figure 2. Trametinib suppresses phosphorylation of ERK1/2 in T and B cells. (A) PBMCs were isolated from patients and stimulated with PMA and ionomycin for
15 minutes. Expression of phosphorylated ERK1/2 by CD41 T, CD81 T cells, and CD191 B cells was analyzed after treatment (or not) with trametinib and tacrolimus (10 nM,
100 nM, and 1 mM). The numbers represent the frequencies of phospho-ERK1/2 cells compared with controls. (B) Aggregated percentages of cells CD41/CD81 T and
CD191 B cells showing phosphorylated ERK1/2 expression with PMA/Ionomycin stimulation for 4 hours (data expressed as means 6 SEMs; n 5 4 per group, gray; PMA and
ionomycin stimulation, red; unstimulated). *P , .05; **P , .01; ***P , .001; ****P , .0001 (unpaired 2-tailed Student t test).
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